Mandate

Vinge advises on equity line and rights issue guarantee to Karo Bio

October 27, 2010

Azimuth Opportunity, Inc and Karo Bio AB (publ) (NASDAQ OMX Stockholm) have entered an agreement regarding a so-called Equity Credit Facility, whereby Azimuth has undertaken to subscribe for new shares in Karo Bio on Karo Bio’s request and as set out in the terms of the facility, of up to USD 35 million. In addition, Azimuth guarantees part of Karo Bio’s rights issue of approx. SEK 300 million. The Facility and the rights issue are subject to approval by the general meeting of Karo Bio.

Vinge advises Azimuth. Vinge’s team is headed by capital markets partner Erik Sjöman.

Related

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge advises Studentbostäder i Norden AB (publ) in connection with its issuance of bonds in an amount of SEK 500 million and its early redemption of outstanding bonds

Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
March 12, 2026